B. Riley Wealth Advisors’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

B. Riley Wealth Advisors’s Portfolio PVCT Stock Details PVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-28,000	Closed	-$11K	–	634
2015 Q4	$11K	Hold	28,000	–	–	﹤0.01%	561
2015 Q3	$17K	Buy	28,000 +10,000	+56%	+$5.12K	﹤0.01%	552
2015 Q2	$10K	Hold	18,000	–	–	﹤0.01%	526
2015 Q1	$15K	Buy	18,000 +4,000	+29%	+$3.3K	﹤0.01%	567
2014 Q4	$11	Hold	14,000	–	–	﹤0.01%	2843
2014 Q3	$14K	Sell	14,000 -11,000	-44%	-$10.7K	﹤0.01%	643
2014 Q2	$21.5K	Buy	+25,000	New	+$30K	0.01%	1434

Other funds holding PVCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

HFBOT

Home Federal Bank of Tennessee Knoxville, Tennessee $463M AUM 24.62% 1-Year Est. Return

CCB

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

B. Riley Wealth Advisors's PVCT Position: Q1 2016 in Review

B. Riley Wealth Advisors sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q1 2016, closing a stake of 28,000 shares — an estimated $11K sold.

B. Riley Wealth Advisors first reported a position in PVCT in Q2 2014 and held it in 7 quarters. The position peaked at $21.5K in Q2 2014. 44 funds tracked by Wall St. Rank hold PVCT as of Q1 2016.

B. Riley Wealth Advisors reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q1 2016 after selling out during the quarter.
B. Riley Wealth Advisors sold 28,000 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q1 2016, an estimated $11K.
B. Riley Wealth Advisors first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q2 2014 and held it in 7 quarters.
B. Riley Wealth Advisors's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $21.5K in Q2 2014.
44 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q1 2016.

Based on B. Riley Wealth Advisors's 13F filing for Q1 2016, filed 16 May 2016.